Project Grant R01CA318448
Award Date 8/11/26
Completion Date 7/31/30
Dollars Obligated $732K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $693,290 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to perform whole-slide multiplex immunofluorescence tissue imaging analysis of 450 stage II/III primary invasive melanomas from the INTERMEL case-control study, focusing on immune cell and tumor vasculature markers to identify spatial tumor microenvironment signatures that distinguish aggressive from indolent disease....
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $137,631 on July 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund research on mutant splicing factor-derived protein isoforms in clonal hematopoietic disorders and antigen presentation. The award funds basic research investigating how somatic mutations in RNA splicing factor genes (U2AF1, SF3B1, and SRSF2) drive myelodysplastic syndromes and related clonal hematopoietic conditions. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $140,400 on July 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop multimodal, interpretable artificial intelligence models that integrate digital pathology images and tumor genomic data to improve precision cancer diagnosis and treatment selection. The award funds a two-phase K99/R00 career development grant. During the K99 phase, the recipient will study multimodal self-supervised...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $444,590 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms. The research builds on a prior Phase I/II study (MPD-RC 109) testing combination therapy with the JAK1/2 inhibitor ruxolitinib and the hypomethylating agent decitabine in advanced MPN...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $676,849 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to enhance MIRDSOFT.ORG, an open-source radiation dosimetry platform operated by the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging. The award funds development of computational human phantoms and dosimetry software to support personalized dose estimation in nuclear medicine and radiology. Deliverables...